Copenhagen’s Biograil raises €20 million for oral drug delivery device designed as an alternative to injections
Biograil, a Copenhagen-based BioTech company developing an oral device to deliver therapeutics that would otherwise require injection, has closed a €20 million funding round. The round was backed by Verve Ventures and Megatrend Invest. HTGF, which led the company’s Seed syndicate in 2019, participated through its HTGF Opportunity growth fund. In July 2025, the company […] The post Copenhagen’s…
We haven't written up this one. EU-Startups has the full story — the link below goes straight to it.
